Cigna earnings beat by $0.04, revenue topped estimates
Jeremy Rossen, Executive Vice President and General Counsel of Ziff Davis, Inc. (NASDAQ:ZD), recently acquired 1,000 shares of the company’s common stock. The transaction, dated March 5, 2025, was executed at a price of $38.015 per share, amounting to a total value of $38,015. The purchase comes as the stock trades near its 52-week low of $37.76, with InvestingPro analysis indicating the company is currently undervalued.
Following this acquisition, Rossen’s total holdings in Ziff Davis increased to 2,000 shares held indirectly through The Jeremy and Gina Rossen Family Trust. This adjustment reflects a correction, as 1,000 Restricted Stock Units (RSUs) were previously misclassified under direct holdings. The company maintains impressive gross profit margins of 85.7% and boasts strong fundamentals. InvestingPro subscribers have access to 14 additional key insights about Ziff Davis’s financial health and valuation metrics.
Rossen’s transactions are part of routine filings that provide transparency into the trading activities of company insiders. Investors often monitor these filings to gauge insider confidence in the company’s prospects. Technical indicators from InvestingPro suggest the stock is currently in oversold territory, potentially presenting an opportunity for value investors.
In other recent news, Ziff Davis Inc. reported its financial results for Q4 2024, achieving an adjusted diluted earnings per share (EPS) of $2.58, slightly exceeding the forecast of $2.57. However, the company reported revenue of $412.8 million, which fell short of the expected $423.87 million. Despite the earnings beat, the revenue miss impacted investor sentiment. Looking ahead, Ziff Davis anticipates a revenue growth midpoint of 5% for 2025, with an adjusted EBITDA growth midpoint of 6%. The company expects growth across all five segments, with stronger performance projected for the latter half of the year.
In addition to the earnings results, Citi analysts adjusted their outlook on Ziff Davis, lowering the stock’s price target from $58.00 to $52.00 while maintaining a Neutral rating. This adjustment was made following a review of the company’s fourth-quarter results and full-year 2025 guidance. Analysts at Citi highlighted ongoing challenges, particularly in the B2B Tech segment, and potential risks associated with GenAI Search. Despite these challenges, management expressed confidence in returning to growth across all segments in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.